Literature DB >> 31135632

Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States.

Grishma Hirode1, Eric Vittinghoff2, Robert J Wong1.   

Abstract

GOALS: The aim of this study was to understand the burden of nonalcoholic fatty liver disease (NAFLD) among hospitalized patients in the United States.
BACKGROUND: A major driver of the rapidly increasing US clinical and economic burden of NAFLD is attributed to inpatient health care resource utilization.
METHODS: We performed a cross-sectional study of the 2007 to 2014 Nationwide Inpatient Sample. A total of 481,122 hospitalizations in patients with NAFLD were identified using ICD-9 codes after excluding other etiologies of chronic liver disease. We analyzed survey-weighted annual trends in national estimates of hospitalizations in patients with NAFLD, stratified by metabolic comorbidities, cirrhosis, and other liver-related complications. Annual trends in total hospitalization charges were inflation adjusted to 2014 USD.
RESULTS: From 2007 to 2014, hospitalizations in patients with NAFLD increased by 83.4% (42,060 to 77,143, P<0.0001), and the proportion of total hospitalizations represented by patients with NAFLD increased by 104.4% (6.34 to 13.0 per 1000 hospitalizations). During this time, there was a 159% increase in total inpatient hospitalization charges in patients with NAFLD ($7.7 billion in 2007 to $19.9 billion in 2014, P<0.001). This increasing clinical and economic burden was observed across all metabolic comorbidities and liver complications evaluated among hospitalizations in patients with NAFLD.
CONCLUSIONS: With the rising prevalence of NAFLD in the United States, the inpatient clinical and economic burden of NAFLD is also rapidly rising. In 2014, total estimated national hospitalization charges in patients with NAFLD reached nearly $20 billion, with metabolic comorbidities and liver-related complications being major contributors to this rising burden.

Entities:  

Year:  2019        PMID: 31135632     DOI: 10.1097/MCG.0000000000001229

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

Review 1.  Using Telehealth for Diagnosis and Management of Non-Alcoholic Fatty Liver Disease.

Authors:  Hamid-Reza Moein; Elvis J Arteaga; Souvik Sarkar
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-04-29

2.  PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling.

Authors:  Ning Ma; Yi-Kang Wang; Sheng Xu; Qian-Zhi Ni; Qian-Wen Zheng; Bing Zhu; Hui-Jun Cao; Hao Jiang; Feng-Kun Zhang; Yan-Mei Yuan; Er-Bin Zhang; Tian-Wei Chen; Ji Xia; Xu-Fen Ding; Zhen-Hua Chen; Xiu-Ping Zhang; Kang Wang; Shu-Qun Cheng; Lin Qiu; Zhi-Gang Li; Yong-Chun Yu; Xiao-Fan Wang; Bin Zhou; Jing-Jing Li; Dong Xie
Journal:  Nat Commun       Date:  2021-05-24       Impact factor: 14.919

Review 3.  Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Authors:  Hannah K Drescher; Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Cells       Date:  2019-08-07       Impact factor: 6.600

4.  Hospital outcomes and early readmission for the most common gastrointestinal and liver diseases in the United States: Implications for healthcare delivery.

Authors:  Somashekar G Krishna; Brandon K Chu; Alecia M Blaszczak; Gokulakrishnan Balasubramanian; Hisham Hussan; Peter P Stanich; Khalid Mumtaz; Alice Hinton; Darwin L Conwell
Journal:  World J Gastrointest Surg       Date:  2021-02-27

5.  Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.

Authors:  Jingrui Wang; Zhenzhen Su; Yijin Feng; Ruihan Xi; Jiamin Liu; Peixi Wang
Journal:  BMC Gastroenterol       Date:  2021-12-19       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.